1. At a Glance
Beta Drugs is not just another pharma stock. It’s a 5x multibagger SME graduate, armed with high ROE, a strong grip on oncology, and a secret wish to become India’s next Divi’s Lab—without the dividend distractions.
2. Introduction with Hook
If the pharma world had a B-school, Beta Drugs would be the ambitious topper who skipped fests to work on a breakthrough anti-cancer molecule.
- 5-Year Profit CAGR: 37%
- FY25 Revenue: ₹362 Cr | Net Profit: ₹42 Cr
- ROE: A boss-level 26%
But… no dividends. No margin of error. And now a bet on exports, API, and the Mexican market (Hola COFEPRIS). Can Beta sustain the hype?
3. Business Model (WTF Do They Even Do?)
Beta Drugs Ltd manufactures a wide range of oncology (anti-cancer) drugs, both injectables and tablets. It supplies:
- Hospitals & oncology chains in India
- Export markets (especially after receiving COFEPRIS—Mexico approval)
- APIs and finished formulations to global clients
They’re in the sweet (and painful) spot of Indian pharma—focused oncology. With over 30+ key products and multiple top-5 ranked molecules in India, it isn’t just surviving; it’s
